Nevada Cancer Institute-

Las Vegas, Nevada 89135

0 studies enrolling now · 69 studies all time

What they study most

AML, Adenocarcinoma of the Colon, Alzheimer's Disease, B Cell Lymphoma, B-Cell Lymphoma, Bladder Cancer, Breast Cancer, Cancer, Cancer, Malignant Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Chronic Lymphocytic Leukemia

Studies at this site

• Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer — Completed
• Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer — Completed
• Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer — Completed
• Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer — Completed
• A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin — Completed
• Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442) — Completed
• Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer — Completed
• S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy — Completed
• Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) — Completed
• A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer — Stopped early
• Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone — Stopped early
• A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors — Completed
• BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab — Stopped early
• Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases — Completed
• Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma — Completed
• Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function — Completed
• A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma — Completed
• S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases — Completed
• Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy — Completed
• Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy — Completed
• Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer — Completed
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed
• Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer — Completed
• Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody — Completed
• Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) — Completed
• Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) — Completed
• Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer — Completed
• Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) — Completed
• Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors — Completed
• Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) — Completed
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML — Completed
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer — Completed
• Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease — Completed
• Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma — Completed
• First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy — Completed
• A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease — Completed
• MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma — Stopped early
• A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies — Completed
• BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors — Completed
• Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) — Completed
• Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL — Completed
• A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) — Completed
• Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab — Completed
• A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) — Stopped early
• Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia — Completed
• Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer. — Completed
• Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer — Completed
• A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer — Completed
• Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) — Completed